Emisphere drug proves positive in dog studies
-
- April
- 16
Emisphere Technologies Inc. reported today that studies involving dogs have provided additional evidence that a technology the company is developing enhances absorption of oral vitamin B12 supplements.
The results confirm an earlier report of effectiveness in studies conducted in rats using Emisphere’s Eligen technology, which reportedly improves absorption of orally administered drugs.
About 40 million Americans undergo annual B12 injections to treat a variety of serious medical conditions. An addition 5 million people yearly consume more than 600 million B12 tablets in various strengths as nutritional supplements, Emisphere said.
This entry was posted
on Wednesday, April 16th, 2008 at 2:55 pm by David Schepp.
You can follow any responses to this entry through the RSS 2.0 feed.
Category: Biopharmaceutical, Drug development, Drug testing, Pharmaceutical
Print
| 
Email
